Imedex, LLC is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.be.
Perspectives in Melanoma XIV is designated for a maximum of 9 hours of European external CME credits. Each medical specialist should claim only those hours of credit that she/he actually spent in the educational activity.
EACCME credits are recognized by the American Medical Association toward the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA Category 1 credit, contact the AMA.
Who Should Attend
This educational activity is specifically designed for medical and surgical oncologists, dermatologists, and other physicians, physicians-in-training, and researchers interested and/or involved in the treatment of patients with melanoma and its associated complications.
Educational Objectives
Upon completion of this educational activity, attendees should be able to:
- Identify at least two important aspects regarding the epidemiology, biology, and/or the pathogenesis of melanoma and how they would impact the treatment of melanoma
- Evaluate at least two biomarkers and the potential impact of these biomarkers on the treatment and management of melanoma
- Identify at least two recent advances in diagnostic and imaging methodologies
- Describe the role of the immune system in melanoma pathogenesis and identify at least two immunological targets for therapy
- Discuss the molecular biology and therapeutic potential of targeting signal transduction pathways and how novel resistance patterns are evolving
Philippe Autier, MD, MPH
International Prevention Research Institute
Lyon, France
Raymond L. Barnhill, MD
Hôpital Saint-Louis, Université Paris VII
Paris, France
Jan Willem Coebergh, MD, PhD
Erasmus University Medical Center
Rotterdam, The Netherlands
Robert S. Coffin, PhD
BioVex, Inc
Woburn, Massachusetts, United States
Reinhard Dummer, MD
University Hospital of Zurich
Zurich, Switzerland
Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands
Keith T. Flaherty, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
John B.A.G. Haanen, MD, PhD
Netherlands Cancer Institute
Antoni van Leeuwenhoek Hospital
Amsterdam, The Netherlands
Axel Hoos, MD, PhD
Bristol-Myers Squibb
Wallingford, Connecticut, United States
John M. Kirkwood, MD
University of Pittsburgh Medical Center
Hillman Cancer Research Center
Pittsburgh, Pennsylvania, United States
Lionel Larue, PhD, HDR
Institut Curie
Orsay, France
Richard Marais, PhD
The Institute of Cancer Research
London, United Kingdom
Steven J. O’Day, MD
The Angeles Clinic and Research Institute
Santa Monica, California, United States
Poulam M. Patel, PhD, FRCP
University Nottingham
Nottingham, United Kingdom
Giovanni Pellacani, MD
University of Modena and Reggio Emilia
Modena, Italy
Caroline Robert, MD
Institut Gustave Roussy
Villejuif, France
Dirk Schadendorf, MD
University Hospital Essen
Essen, Germany
Ton N. Schumacher, PhD
The Netherlands Cancer Institute
Amsterdam, The Netherlands
Alan Spatz, MD
McGill University
Jewish General Hospital
Montreal, Quebec, Canada
Alessandro Testori, MD
European Institute of Oncology
Milan, Italy
Claudio Dansky Ullmann, MD
National Cancer Institute
Bethesda, Maryland,United States
Alexander C. J. van Akkooi, MD
Erasmus University Medical Center
Daniel den Hoed Cancer Center
Rotterdam, The Netherlands
Christiane A. Voit, MD, PhD
Charité University Medicine Berlin
Berlin, Germany
Hassane M. Zarour, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Friday, 17 September, 2010
9:00
Welcome Address
9:05
Audience response system outcomes evaluation
Session I: Updates in epidemiology, genetics, and basic research
Moderators: Jan Willem Coebergh, MD, PhD and Alan Spatz, MD
9:15
UVA versus UVB – the Iceland story revisited
Philippe Autier, MD, MPH
9:35
New molecular classification system proposals
Alan Spatz, MD
9:55
Melanoma stem cells
Lionel Larue, PhD, HDR
10:15
Angiotropism and extravascular migratory metastasis in melanoma
Raymond L. Barnhill, MD
10:35 Coffee Break
Session II: Updates in diagnostics and surgery
Moderators: Alessandro Testori, MD and
John B.A.G. Haanen, MD, PhD
11:00
Confocal microscopy for diagnosis in the clinic
Giovanni Pellacani, MD
11:20
New developments with ultrasound for staging of primary melanoma
Christiane A. Voit, MD, PhD
11:40
Electrochemotherapy from superficial to visceral metastases
Alessandro Testori, MD
12:00
Complete lymph node dissection: mandatory or an option for whom?
Alexander C.J. van Akkooi, MD
12:20
Panel discussion
12:30
Lunch
Session III: Systemic therapies:
Novel small molecule inhibitors and resistance
Moderators: John M. Kirkwood, MD and Poulam M.Patel, PhD, FRCP
14:00
Importance of pathways: How do they relate to resistance patterns?
Richard Marais, PhD
14:25
Resistance patterns and new combinations
Keith T. Flaherty, MD
14:50
Overview of non-PLX inhibitors
Reinhard Dummer, MD
15:15
Panel discussion
15:30
Break
Session IV: Oral abstract presentations
16:00
Presentation of selected abstracts
17:45
Audience response outcomes evaluation
18:00
Adjourn
Saturday, 18 September 2010
8:30
Introduction to day two
8:35
Audience response system outcomes evaluation
Session V: Immunomodulators, vaccinations, and resistance
Moderators: Alexander M.M. Eggermont, MD, PhD and Caroline Robert, MD
8:45
anti-CTL-A4
Steven J. O’Day, MD
9:05
Immunity to NY-ESO-1: Overcoming the mechanisms of melanoma-induced immunosuppression
Hassane M. Zarour, MD
9:25
Immuno-oncology: Creating the framework for a new era of cancer therapy
Axel Hoos, MD, PhD
9:50
Dissecting therapy-induced T-cell responses in melanoma
Ton N. Schumacher, PhD
10:10
Panel discussion
10:20
Break
Session VI: Oral abstract presentations
Moderators: Dirk Schadendorf, MD and John B.A.G. Haanen, MD, PhD
10:45
Presentation of selected abstracts
11:15
Special address to the melanoma community
Valerie Guild of the AIM at Melanoma Foundation
11:25
Lunch
Session VII: Clinical trial overview
Moderators: John M. Kirkwood, MD and
Alexander M.M. Eggermont, MD, PhD
12:25
CTEP melanoma update
Claudio Dansky Ullmann, MD
12:45
Ipilimumab in stage IV
Steven J. O’Day, MD
12:50
Ipilimumab in stage III
Alexander M.M. Eggermont, MD, PhD
12:55
Tremelimumab in stage IV
Caroline Robert, MD
13:05
Phase III BRAF and c-KIT trials
Keith T. Flaherty, MD
13:15
GM-CSF-encoding oncolytic herpes simplex virus
Robert S. Coffin, PhD
13:25
Tasisulam
John M. Kirkwood, MD
13:35 Audience response outcome measurement
13:45 Closing comments
14:00 Adjourn
Registration Fees:
Discounted......................................... €399.00
If payment received by 22 July 2010
Regular...............................................€499.00
If payment received by 9 September 2010
Full/Onsite..........................................€599.00
If payment received after 9 September 2010
Nurses/Residents/Fellows*...................€199
*proof of eligibility must accompany registration
Pharmacists*...................................... €299
*proof of eligibility must accompany registration
EORTC member discount*..................- €100
*proof of eligibility must accompany registration
If you are attending the EORTC meeting on Thursday, 16 September 2010 you will need to register
separately for this meeting. The EORTC meeting is open to EORTC members only.
To Register:
You may register online 9 September 2010 at www.imedex.com, by calling Imedex at +1 678.242.0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the Congress.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
EORTC members receive an additional €100 off the published registration fees.
Payment:
To pre-register, registration and payment must be received no later than 9 September 2010. Please register onsite after this date. Contact Imedex at +1 678.242.0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: Melanoma 14 178.01. An attendee is not registered until full payment is received.
Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.
Registration Fee Inclusions:
Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.
Cancellation:
For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 9 September 2010. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 9 September 2010.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this Congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
NOVOTEL Amsterdam City
Europaboulevard 10
NL-1083 AD Amsterdam
Tel: (+31)20/5411123
Fax: (+31)20/6462823
E-mail: H0515@accor.com
www.novotelamsterdamcity.com
Novotel Amsterdam City is a 4-star hotel in the heart of Amsterdam's business district, right by the Amsterdam RAI Exhibition and Convention Center and close to the WTC. RAI station is only a short walk away and offers frequent connections to Amsterdam city center and Schiphol, making the hotel ideal for both business trips and weekend breaks.
For the convenience of attendees, a limited number of rooms have been reserved until 1 August 2010 at a discounted rate of €175.00 single occupancy or €195.00 double occupancy, plus city tax, currently at 5%. The rate includes breakfast and other taxes. This rate is not guaranteed outside the Congress dates or after 1 August 2010.
To reserve your room please complete the attached form and return to the Novotel Amsterdam City either by fax at +31 (0)20 – 646 28 23 or email to H0515-SB@accor.com. To receive the group rate you please reference “Imedex” in your fax or email. Reservations made using the hotel’s website or by calling the hotel directly will not receive the group rate. The hotel form can also be accessed on the meetings website under Accommodations.
Click here for the the hotel registration form.
Dear Colleague,
It is with great pleasure that we invite you to join us for Perspectives in Melanoma XIV! This fall’s conference, 17-18 September 2010 in Amsterdam, The Netherlands, promises to be an outstanding educational event.Perspectives in Melanoma XIV is an exciting multi-disciplinary forum that will provide a comprehensive overview of recent advances and rigorous discussions of the most current and controversial topics in the fields of melanoma diagnosis, clinical research, and contemporary therapy. This congress will appeal to those interested and/or involved in the treatment of melanoma and its consequences, including medical and surgical oncologists, dermatologists, researchers and other healthcare professionals.
Led by authorities and current investigators in the field, the program will cover several of the most promising and important on-going clinical trials. State-of-the-art presentations by experts in molecular biology, genetics, and immunology will provide a valuable educational experience for all melanoma-related disciplines.
Additionally, Perspectives in Melanoma XIV is preceded by the EORTC Melanoma Group Meeting, held on 16 September2010. If you are a member of the EORTC Melanoma Group, please be sure to schedule a few extra days out of the office to attend both meetings.
We look forward to welcoming you in Amsterdam to Perspectives in Melanoma XIV. Your diverse perspectives and contributions add immeasurable value to this international program.
Sincerely,
Alexander M.M. Eggermont, MD, PhD, Chair
John M. Kirkwood, MD, Chair
Organizer
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740, USA
T: +1 770.751.7332
F: +1 770.751.7334
E: meetings@imedex.com
W: www.imedex.com
Congress Location and Registration
NOVOTEL Amsterdam City
Europaboulevard 10
NL-1083 AD Amsterdam
Tel: (+31)20/5411123
Fax: (+31)20/6462823
E-mail: H0515@accor.com
www.novotelamsterdamcity.com
This activity is presented under the
auspices of the European
Organization for Research and
Treatment of Cancer.
This Congress is endorsed by the following societies, associations, and foundations:
Chairs
Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands
John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Important Dates
Discounted Registration Deadline
22 July 2010
Abstract Submission Deadline
5 August 2010
Abstract Notifications Mailed
19 August 2010
Abstract Presenter Registration Deadline
2 September 2010
Regular Registration Deadline
9 September 2010
EORTC Melanoma Group Meeting
16 September 2010
Presentation Dates
17-18 September 2010
Italian Participants
Alijet & Fargo International SRL has been appointed as the official agency for government authorization for Italian participants.
You may contact them directly at:
Alijet & Fargo International SRL
Via Pietro Maroncelli 44/66, 50137 Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda's content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES' RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual's own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2010 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following companies are supporters of this Congress:
Bronze
Faculty Travel Grant
Several options are available to companies interested in supporting this Congress.
For more information, please contact Imedex at +1 770.751.7332, or by email at cme@imedex.com.
Opportunities are available to companies interested in exhibiting at this Congress.
For more information, please contact Cori Gunter at +1 678.242.0712, or by email at c.gunter@imedex.com.
